

Budesonide orodispersible tablets (Jorveza® ▼) for inducing remission of eosinophilic oesophagitis in adults

The Pan Mersey Area Prescribing Committee recommends the prescribing of BUDESONIDE orodispersible tablets (Jorveza® ▼), by specialists only, as a treatment option for inducing remission eosinophilic oesophagitis in adults (older than 18 years of age) in accordance with NICE TA708.

RED

[NICE Technology Appraisal \(TA\) 708¹](#) (23 June 2021) recommends budesonide orodispersible tablet (ODT) (Jorveza® ▼) as a treatment option **ONLY** for inducing remission of eosinophilic oesophagitis in adults.

Although budesonide ODT has a marketing authorisation for both **inducing** and **maintaining** remission in eosinophilic oesophagitis, at the time this appraisal started it was only licensed for induction. **So, the company's evidence is for inducing remission only** (with treatment of up to 12 weeks) and therefore the NICE committee is unable to make recommendations for maintenance treatment.

There is currently no standard care for inducing remission in eosinophilic oesophagitis. NICE deems there is an unmet need for this condition.

Prescribing must be initiated and retained by specialists working in gastroenterology.

NICE do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £9,000 per 100,000 population. This is because the overall incremental cost of treatment is low and eosinophilic oesophagitis is a rare condition affecting around 13,000 people in England.

The cost of a 12 week treatment course at the recommended dose of 1mg twice daily, is £602 at NHS list price.²

References

1. National Institute for Health and Care Excellence. Technology Appraisal 708. [Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis](#), 23 June 2021. Accessed 25 June 2021.
2. NHS Business Services Authority. [Dictionary of medicines and devices \(dm+d\) browser](#). Accessed online 08 June 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.